# Nuclide record nct06726161 (trial). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/trials/nct06726161/>
  a schema:MedicalTrial ;
  nuclide:kind "trial" ;
  schema:identifier "nct06726161", "NCT06726161" ;
  schema:name "Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC"@en ;
  schema:description "A phase 1/2 trial of RYZ801 in hepatocellular carcinoma, run by RayzeBio, Inc., now recruiting."@en ;
  schema:url <https://nuclide.cc/trials/nct06726161/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06726161> ;
  nuclide:status "recruiting" ;
  nuclide:tag "pipeline", "ctgov-ingest" ;
  nuclide:phase "1/2" ;
  nuclide:indications <https://nuclide.cc/indications/hcc/> ;
  nuclide:companies <https://nuclide.cc/companies/rayzebio/> .